Related Experiment Video
Updated: Jun 26, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
EGFR, HER-2 and COX-2 levels in colorectal cancer
A G Antonacopoulou1, A C Tsamandas, T Petsas
1Clinical Oncology Laboratory, School of Medicine, University of Patras, Rion, Patras, Greece.
Aims:
Receptor tyrosine kinases epidermal growth factor receptor (EGFR) and HER-2 and cyclooxygenase-2 (COX-2) are promising molecular targets for cancer therapy and/or prevention. The aim was to evaluate EGFR, HER-2 and COX-2 mRNA and protein expression in colorectal cancer patients.
Methods And Results:
EGFR, HER-2 and COX-2 protein levels were evaluated by immunohistochemistry in malignant tissue, dysplastic tissue and normal mucosa samples from 124 cases with primary colorectal carcinoma. Moreover, the corresponding mRNA levels were assessed by quantitative reverse transcriptase-polymerase chain reaction in 46 colorectal carcinomas. There was strong correlation between mRNA and protein expression for EGFR (P < 0.001), HER-2 (P < 0.004) and COX-2 (P < 0.007). EGFR levels did not correlate with stage of the disease or tumour differentiation. HER-2 and COX-2 levels increased in advanced stages and in differentiated carcinomas. Furthermore, a correlation between HER-2 and COX-2 expression was revealed in neoplastic tissue.
Conclusions:
EGFR as well as HER-2 and COX-2 overexpression represent important alterations that are related to the molecular pathways underpinning colorectal carcinogenesis. Further investigation is required to evaluate the impact of these markers on the management of patients with colorectal cancer.
Insights
Epidermal growth factor receptor (EGFR), HER-2, and cyclooxygenase-2 (COX-2) protein and mRNA levels were evaluated in colorectal cancer patients. These molecular targets showed overexpression in advanced stages and correlated with colorectal carcinogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor receptor (EGFR), HER-2, and cyclooxygenase-2 (COX-2) are recognized as key molecular targets in cancer therapy and prevention.
- Understanding the expression patterns of these targets in colorectal cancer is crucial for developing effective treatment strategies.
Purpose of the Study:
- To investigate the mRNA and protein expression levels of EGFR, HER-2, and COX-2 in patients with colorectal cancer.
- To determine the correlation between these molecular markers and clinicopathological features of colorectal carcinoma.
Main Methods:
- Protein expression of EGFR, HER-2, and COX-2 was assessed using immunohistochemistry in 124 colorectal carcinoma samples (malignant, dysplastic, and normal tissues).
- mRNA levels of these targets were quantified via reverse transcriptase-polymerase chain reaction in 46 colorectal carcinoma samples.
- Statistical analysis was performed to evaluate correlations between mRNA and protein expression, and between marker levels and disease characteristics.
Main Results:
- A significant correlation was observed between mRNA and protein expression for EGFR, HER-2, and COX-2 (P < 0.001, P < 0.004, P < 0.007, respectively).
- EGFR expression did not correlate with disease stage or tumor differentiation.
- HER-2 and COX-2 levels were found to be elevated in advanced stages and differentiated colorectal carcinomas, with a positive correlation between HER-2 and COX-2 expression in neoplastic tissues.
Conclusions:
- Overexpression of EGFR, HER-2, and COX-2 are significant molecular alterations implicated in colorectal carcinogenesis.
- These markers are associated with advanced disease stages and differentiated tumor types, suggesting their role in tumor progression.
- Further research is warranted to explore the clinical utility of these markers in managing colorectal cancer patients.
